Increased mortality after an acute heart failure episode: New pathophysiological insights from the RELAX-AHF study and beyond

Current Heart Failure Reports

Volumn 11, Issue 1, 2014, Pages 19-30

  Cotter, Gad ^a   Milo, Olga ^a   Davison, Beth A ^a  

^a Momentum Research Inc   (United States)

Author keywords

Heart failure; Mortality; Serelaxin

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALISKIREN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYSTATIN C; ENDOTHELIN 1; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; NESIRITIDE; NORADRENALIN; PLACEBO; RELAXIN; ROLOFYLLINE; SERELAXIN; TEZOSENTAN; TOLVAPTAN; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; URIC ACID; VALSARTAN;

ACUTE HEART FAILURE; APOPTOSIS; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CYTOKINE RELEASE; DYSPNEA; ELEVATED BLOOD PRESSURE; GASTROINTESTINAL TRACT FUNCTION; GLOMERULUS FILTRATION RATE; HEART DISEASE; HEART FAILURE; HEART MUSCLE INJURY; HEART OUTPUT; HUMAN; KIDNEY DYSFUNCTION; LIVER FUNCTION; LUNG EDEMA; MODERATE RENAL IMPAIRMENT; OXYGENATION; PATHOPHYSIOLOGY; PERFUSION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UREA NITROGEN BLOOD LEVEL;

ACUTE DISEASE; GASTROINTESTINAL DISEASES; HEART FAILURE; HUMANS; KIDNEY DISEASES; LIVER DISEASES; NEUROTRANSMITTER AGENTS; RECOMBINANT PROTEINS; RELAXIN;

EID: 84896873249     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-013-0180-6     Document Type: Article

References (83)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388-442. These are the official guidelines of the European society of cardiology for the diagnosis and treatment of HF including AHF.
2. O'Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J. 2010;159:841-9. This study shows the very high rates of readmission and death in acute heart failure.
3. Huesch MD, Ong MK, Fonarow GC. Measuring heart failure care by 30-day readmission: rethinking the quality of outcome measures. Am Heart J. 2013;166:605-9.
4. Jong P, Vowinckel E, Liu PP, Gong Y, Tu JV. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med. 2002;162:1689-94.
5. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JEA, Cleland JG, et al. Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail. 2010;12:423-33.
6. Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2003;42:140-7. (Pubitemid 36760775)
7. Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JCHF 2013; 1103-11.
8. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA. 2007;298:2009-19. (Pubitemid 350074798)
9. Gheorghiade M, Konstam MA, Burnett Jr. JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA. 2007;297:1332-43. (Pubitemid 46513234)
10. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;363:1419-28.
11. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW, ADHERE Scientific Advisory Committee and Investigators. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2007;153:1021-8. The ADHERE registry is the largest AHF registry to date that represent some critical characteristics of patients with AHF in real life. (Pubitemid 46809844)
12. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-Preserve) trial. Circulation. 2010;121:1393-405.
13. Abrahamsson P, Swedberg K, Borer JS, Böhm M, Kober L, Komajda M, et al. Risk following hospitalization in stable chronic systolic heart failure. Eur J Heart Fail. 2013;15:885-91. This is an important manuscript showing the large increased risk of mortality after an AHF event in patients with stable chronic HF.
14. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381:29-39. This is an important paper that for the first time suggests that early intervention in the first 2 days of an AHF admission may be beneficial.
15. Colombo PC, Ganda A, Lin J, Onat D, Harxhi A, Iyasere JE, et al. Inflammatory activatio: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev. 2012;17:177-90. An important review of inflammatory changes and their role in the cardio renal axis in HF.
16. Floras JS. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol. 1993;22(suppl):72A-84.
17. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler MD. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 1995;26:1257-63.
18. Lee CS, Tkacs NC. Current concepts of neurohormonal activation in heart failure: mediators and mechanisms. AACN Adv Crit Care. 2008;19:364-85.
19. Chaggar PS, Malkin CJ, Shaw SM, Williams SG, Channer KS. Neuroendocrine effects on the heart and targets for therapeutic manipulation in heart failure. Cardiovasc Ther. 2009;27:187-93.
20. Rea ME, Dunlap ME. Renal hemodynamics in heart failure: implications for treatment. Curr Opin Nephrol Hypertens. 2008;17:87-92. (Pubitemid 350295203)
21. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-847.
22. Boulanger CM. Secondary endothelial dysfunction: hypertension and heart failure. J Mol Cell Cardiol. 1999;31:39-49. (Pubitemid 29078217)
23. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin- 1 in heart failure and loss of normal response to postural change. Circulation. 1992;85:510-7.
24. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation. 1992;85:1374-9.
25. Kim HN, Januzzi AL. Natriuretic peptide testing in heart failure. Circulation. 2011;123:2015-9.
26. Felker GM, Hasselblad V, Hernandez AF, O"Connor CM. Biomarker-guided Therapy in Chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009;158:422-30. This is an excellent paper that summarizes the major clinical trials and provides expert insight on the benefits of measuring natriuretic peptides and their usefulness for individual approach in the treatment of heart failure.
27. Milo O, Cotter G, Kaluski E, Brill A, Blatt A, Krakover R, et al. Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes. Am J Cardiol. 2003;92:222-6. A very important paper that shows in detail the neurohormonal and inflammatory activation in AHF. (Pubitemid 36835978)
28. Mehra MR, Uber PA, Francis GS. Heart failure therapy at a crossroad: are there limits to the neurohormonal model? J Am Coll Cardiol. 2003;41:1606-10. (Pubitemid 36543382)
29. Gheorghiade M, De Luca L, Bonow RO. Neurohormonal inhibition in heart failure: insights from recent clinical trials. Am J Cardiol. 2005;96:3L-9.
30. Coletta AP, Cleland JG. Clinical trials update: highlights of the Scientific Sessions of the XXIII Congress of the European Society of Cardiology - WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Failure. 2001;3:747-50. (Pubitemid 33123176)
31. O'Connor CM, Gattis WA, Adams KF, Hasselblad V, Chandler B, Frey A, et al. Tezosentan in patients with acute heart failure and acute coronary syndromes. J Am Coll Cardiol. 2003;41:1452-7. (Pubitemid 36543358)
32. Kaluski E, Kobrin I, Zimlichman R, Marmor A, Krakov O, Milo O, et al. RITZ-5: randomized intravenous tezosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema. J Am Coll Cardiol. 2003;41:204-10. (Pubitemid 36092185)
33. Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309:1125-35.
34. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32-43. The largest prospective randomized study in AHF.
35. Chen D, Assad-Kottner C, Orrego C, Torre-Amione G. Cytokines and acute heart failure. Crit Care Med. 2008;36:S9-16.
36. Nymo SH, Hulthe J, Ueland T, McMurray J, Wikstrand J, Askevold ET, et al. Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA. Eur J Heart Fail. 2013 Aug 4.
37. Hartog JW, Willemsen S, van Veldhuisen DJ, Posma JL, van Wijk LM, Hummel YM, et al. Effects of alagebrium, an advanced glycation endproduct breaker, on exercise tolerance and cardiac function in patients with chronic heart failure. Eur J Heart Fail. 2011;13:899-908.
38. van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail. 2013;6:219-26.
39. Januzzi Jr. JL, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007;50:607-13. (Pubitemid 47199007)
40. Bozkurt B, Mann DL, Deswal A. Biomarkers of inflammation in heart failure. Heart Fail Rev. 2010;15:331-41.
41. Milo-Cotter O, Cotter-Davison B, Lombardi C, Sun H, Bettari L, Bugatti S, et al. Neurohormonal activation in acute heart failure: results from VERITAS. Cardiology. 2011;119:96-105. An important sub-analysis from VERITAS showing that some inflammatory markers have an independent predictive role of adverse outcomes in AHF.
42. Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1054-60. (Pubitemid 47348231)
43. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010;122:1387-95.
44. Lok SI, Winkens B, Goldschmeding R, van Geffen AJ, Nous FM, van Kuik J, et al. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail. 2012;14:1249-56. This is an excellent manuscript that defines involvement of GDF-15 on several pathological pathways in heart failure, suggesting that GDF-15 changes represent a pathophysiological axis that is not completely addressed in HF.
45. Núñez J, Núñez E, Miñana G, Sanchis J, Bodí V, Rumiz E, et al. Effectiveness of the relative lymphocyte count to predict one-year mortality in patients with acute heart failure. Am J Cardiol. 2011;107:1034-9.
46. Charach G, Grosskopf I, Roth A, Afek A, Wexler D, Sheps D, et al. Usefulness of total lymphocyte count as predictor of outcome in patients with chronic heart failure. Am J Cardiol. 2011;107:1353-6.
47. Milo-Cotter O, Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, et al. Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre-RELAX-AHF study. Cardiology. 2010;117:190-6.
48. Milo-Cotter O, Felker GM, Uriel N, Kaluski E, Edwards C, Rund MM, et al. Patterns of leukocyte counts on admissions for acute heart failure-presentation and outcome - results from a community based registry. Int J Cardiol. 2011;148:17-22. A study that shows that the percentage of lymphocytes is an important predictor of outcome in AHF and may therefore represent an unexplored pathophysiological pathway in AHF.
49. Leuschner F, Rauch PJ, Ueno T, Gorbatov R, Marinelli B, Lee WW, et al. Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. J Exp Med. 2012;209:123-37.
50. Uriel N, Torre-Amione G, Milo O, Kaluski E, Perchenet L, Blatt A, et al. Echocardiographic ejection fraction in patients with acute heart failure: correlations with hemodynamic, clinical, and neurohormonal measures and short-term outcome. Eur J Heart Fail. 2005;7:815-9. This is an important manuscript that suggests that EF is not strongly associated with AHF characteristics. (Pubitemid 41125899)
51. Gandhi SK, Powers JC, Nomeir AM, Fowle K, Kitzman DW, Rankin KM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001;344:17-22. (Pubitemid 32064840)
52. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol. 2013;61:196-206. This is an important manuscript that describes mechanisms through which end organ damage may contribute to the increased mortality after an AHF episode.
53. Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O'Connor CM, Felker GM. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010;56:1071-8.
54. Peacock IV WF, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117-26. (Pubitemid 351679598)
55. You JJ, Austin PC, Alter DA, Ko DT, Tu JV. Relation between cardiac troponin I and mortality in acute decompensated heart failure. Am Heart J. 2007;153:462-70. (Pubitemid 46440690)
56. Felker GM, Hasselblad V, Tang WH, Hernandez AF, Armstrong PW, Fonarow GC, et al. Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. Eur J Heart Fail. 2012;14:1257-64. This is a well-written paper on prevalence of cardiac Troponin elevation among patients admitted with acute heart failure, and its importance in prediction of in-hospital outcome.
57. Fonarow GC, Adams Jr. KF, Abraham WT, Yancy CW, Boscardin WJ, ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572-80. (Pubitemid 40171239)
58. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008;52:347-56. This is another important registry of AHF patients. (Pubitemid 352005813)
59. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581-7. (Pubitemid 37443288)
60. Smith GL, Vaccarino V, Kosiborod M, Lichtman JH, Cheng S, Watnick SG, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail. 2003;9:13-25. (Pubitemid 36356697)
61. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8:136-41. (Pubitemid 34857278)
62. Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail. 2007;13:599-608. An important review of the cardio renal axis in HF. (Pubitemid 47513536)
63. Vallon V, Mühlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev. 2006;86:901-40. (Pubitemid 44033385)
64. Vallon V, Miracle C, Thomson S. Adenosine and kidney function: potential implications in patients with heart failure. Eur J Heart Fail. 2008;10:176-87.
65. Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, et al. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail. 2008;14:631-40.
66. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675-83. (Pubitemid 46205043)
67. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367:2296-304.
68. Zile MR, Bennett TD, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008;118:1433-41.
69. Adamson PB, Magalski A, Braunschweig F, Böhm M, Reynolds D, Steinhaus D, et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol. 2003;19(41):565-71. (Pubitemid 36223320)
70. Vaduganathan M, Greene SJ, Butler J, Sabbah HN, Shantsila E, Lip GY, et al. The immunological axis in heart failure: importance of the leukocyte differential. Heart Fail Rev. 2012 Oct 7.
71. Nikolaou M, Parissis J, Yilmaz MB, et al. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J. 2013;34:742-9. This is an important manuscript that describes in detail the hepatic axis and its importance in AHF.
72. Henrion J, Descamps O, Luwaert R, Schapira M, Parfonry A, Heller F. Hypoxic hepatitis in patients with cardiac failure: incidence in a coronary care unit and measurement of hepatic blood flow. J Hepatol. 1994;21:696-703. (Pubitemid 24374131)
73. Naschitz JE, Slobodin G, Lewis RJ, Zuckerman E, Yeshurun D. Heart diseases affecting the liver and liver diseases affecting the heart. Am Heart J. 2000;140:111-20. (Pubitemid 30471249)
74. Samsky MD, Patel CB, DeWald TA, Smith AD, Felker GM, Rogers JG, et al. Cardiohepatic interactions in heart failure: an overview and clinical implications. J Am Coll Cardiol. 2013;61:2397-405.
75. Cassidy WM, Reynolds TB. Serum lactic dehydrogenase in the differential diagnosis of acute hepatocellular injury. J Clin Gastroenterol. 1994;19:118-21. (Pubitemid 24267564)
76. Henrion J, Schapira M, Luwaert R, Colin L, Delannoy A, Heller FR. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore). 2003;82:392-406. (Pubitemid 37448566)
77. Teichman SL, Unemori E, Dschietzig T, Conrad K, Voors AA, Teerlink JR, et al. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev. 2009;14:321-9.
78. Dschietzig T, Teichman S, Unemori E, Wood S, Boehmer J, Richter C, et al. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail. 2009;15:182-90.
79. Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep. 2010;7:75-82.
80. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009;373:1429-39.
81. Wallentin L. Reducing time to treatment in acute myocardial infarction. Eur J Emerg Med. 2000;7:217-27.
82. Grossman AW, Broderick JP. Advances and challenges in treatment and prevention of ischemic stroke. Ann Neurol. 2013 Aug 8.
83. Capp R, Soremekun OA, Biddinger PD, White BA, Sweeney LM, Chang Y, et al. Impact of physician-assisted triage on timing of antibiotic delivery in patients admitted to the hospital with community-acquired pneumonia (CAP). J Emerg Med. 2012;43:502-8.